Table 1.
Generation | Treatment | |||||
---|---|---|---|---|---|---|
1 | Pexidartinib | Pexidartinib* | Quizartinib | Pexidartinib* | Quizartinib | Pexidartinib* |
2 | Pexidartinib | Pexidartinib* | Quizartinib | Quizartinib | Pexidartinib* | Quizartinib |
3 | Pexidartinib | Pexidartinib* | Quizartinib | Pexidartinib* | Quizartinib | Quizartinib |
4 | Pexidartinib | Pexidartinib* | Quizartinib | Quizartinib | Pexidartinib* | Pexidartinib* |
5 | Pexidartinib | Pexidartinib* | Quizartinib | Pexidartinib* | Quizartinib | Quizartinib |
6 | Pexidartinib | Pexidartinib* | Quizartinib | Quizartinib | Pexidartinib* | Quizartinib |
Figures | 2 | 3 | 4 | 5 | 6 | 7 |
Six treatments were performed, three controls (no rotations) and three rotation experiments where drugs were replaced according to the generations. The three columns to the left represent controls. The cells were treated by quizartinib at IC50, or pexidartinib in two concentrations, one that matches the IC50 and one that matches the IC90 (indicated as Pexidartinib*). The three columns to the right represent the actual rotation experiments in different sequence. Cells were washed after each generation (t = 6 days) to remove any trace of the drug, even for the control arm. Figure numbers refer to the figures showing the results